Advertisement

Gendoping pp 119-137 | Cite as

Gentechnologische Methoden und molekulare Strategien in Doping und Enhancement

  • Patrick Rene DielEmail author
Chapter
  • 1.5k Downloads

Zusammenfassung

Die vervielfältigten Möglichkeiten, die körperliche Leistungsfähigkeit durch Manipulationen zu verändern, ist eine logische Konsequenz der pharmakologischen Forschungsbemühungen und der Ergebnisse der Grundlagenforschung der vergangenen Jahrzehnte. Wurde dies anfangs nur als zusätzliche Gefahr für den Leistungssport wahrgenommen und im Zusammenhang mit Doping diskutiert, so zeigt sich in der Zwischenzeit, dass mehr denn je auch der Breitensport hiervon betroffen ist.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literaturverzeichnis

  1. Corton, J. M., Gillespie, J. G., Hawley, S. A. & Hardie, D. G. (1995). 5‐aminoimidazole‐4‐ carboxamide ribonucleoside. A specific method for activating AMP‐activated protein kinase in intact cells? In European Journal of Biochememistry, 229, S. 558‐565.Google Scholar
  2. Day, T. P. (2014). Advances in AAV Vector Development for Gene Therapy in the Retina. In Advances in Experimental Medicine and Biology, 801, S. 687‐693.Google Scholar
  3. Delcuve, G. P. (2009). Epigenetic control. In Journal of cellular physiology, 219 (2), S. 243‐250.Google Scholar
  4. Feige, J. N., Gelman, L., Michalik, L., Desvergne, B. & Wahli, W. (2006). From molecular action to physiological outputs: peroxisome proliferator‐activated receptors are nuclear receptors at the crossroads of key cellular functions. In Progress in Lipid Research, 45 (2), S. 120‐159.Google Scholar
  5. Gao, W., Kearbey, J. D., Xu, H., Chung, K., He, Y., Marhefka, C. A., Veverka, K. A., Miller, D. D. & Dalton, J. T. (2003). Pharmacodynamics of Selective Androgen Receptor Modulators. In Journal of Pharmacology and Experimental Therapeutics, 304 (3), S. 1334‐1340.Google Scholar
  6. Garba, A. O. & Mousa, S. A. (2010). Bevasiranib for the Treatment of Wet, Age‐Related Macular Degeneration. In Ophthalmology and Eye Diseases, 2, S. 75‐83.Google Scholar
  7. Griggs, R. (2011). Muscular Dystrophies (= Handbook of Clinical Neurology. Band 101). Edinburgh: Elsevier Science.Google Scholar
  8. Huinan, L. (2007). Nanomedicine for implants: A review of studies and necessary experimental tools. In Biomaterials, 28 (2), S. 354‐369. Online‐Quelle:http://www.sciencedirect.com/science/article/pii/S0142961206007630 (letzterZugriff: 09.07.2015).
  9. Hwa V., Oh, Y. & Rosenfeld, R. G. (1999). The insulin‐like growth factor‐binding protein (IGFBP) superfamily. In Endocrine Reviews, 20 (6), S. 761‐787.Google Scholar
  10. Jelkmann, W. (2013). Körpereigene Produktion von Erythropoietin (EPO). In Deutsche Zeitschrift für Sportmedizin, 64 (11), S. 327‐332.Google Scholar
  11. Leung, K. C., Howe, C., Gui, L. Y., Trout, G., Veldhuis, J. D. & Ho, K. K. (2002). Physiological and pharmacological regulation of 20‐kDa growth hormone. In American Journal Physiology, Endocrinology and Metabolism, 283 (4), S. 836‐843.Google Scholar
  12. Lewis, P. (2005). Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. In Cell, 120 (1), S. 15‐20.Google Scholar
  13. Liang, P., Xu, Y., Zhang, X., Ding, C., Huang, R., Zhang, Z., Lv, J., Xie, X., Chen, Y., Li, Y., Sun, Y., Bai, Y., Songyang, Z., Ma, W., Zhou, C. & Huang, J. (2015). CRISPR/Cas9‐ mediated gene editing in human tripronuclear zygotes. In Protein Cell, 6 (5), S. 363‐372.Google Scholar
  14. Ma, K., Mallidis, C., Bhasin, S., Mahabadi, V., Artaza, J., Gonzalez‐Cadavid, N., Arias, J. & Salehian, B. (2003). Glucocorticoid‐induced skeletal muscle atrophy is associated with upregulation of myostatin gene expression. In Am J Physiol Endocrinol Metab,285 (2), S. 363‐371.Google Scholar
  15. Magliano, D. C., Penna‐de‐Carvalho, A., Vazquez‐Carrera, M., Mandarim‐de‐Lacerda, C. A. & Aguila, M. B., (2015). Short‐term administration of GW501516 improves inflammatory state in white adipose tissue and liver damage in high‐fructose‐fed mice through modulation of the renin‐angiotensin system. In Endocrine, 9, [Epub ahead of print].Google Scholar
  16. Michalik, L., Auwerx, J. & Berger, J. P. (2006). International Union of Pharmacology. LXI. Peroxisome proliferator‐activated receptors. In Pharmacological Reviews, 58 (4), S. 726‐741.Google Scholar
  17. Mosler, S., Relizani, K., Mouisel, E., Amthor, H. & Diel, P. (2014). Combinatory effects of siRNA‐induced myostatin inhibition and exercise on skeletal muscle homeostasis and body composition. In Physiological Reports, 2 (3), S. 262‐266.Google Scholar
  18. Sander, D. J. & Keith, J. (2014). CRISPR-Cas systems for editing, regulating and targeting genomes. In Nature Biotechnology, 32, S. 347‐353.Google Scholar
  19. Schuelke, M., Wagner, K. R., Stolz, L. E., Hubner, C., Riebel, T., Komen, W., Braun, T., Tobin, J. F. & Lee, S. J. (2004). Myostatin mutation associated with gross muscle hypertrophy in a child. In New England Journal of Medicine, 350 (26), S. 2682‐2688.Google Scholar
  20. Scott, J. & Phillips, G. C. (2005). Erythropoietin in sports: a new look at an old problem. In Current Sports Medicine Reports, 4 (4), S. 224‐226.Google Scholar
  21. Truong, D. J., Kühner, K., Kühn, R., Werfel, S., Engelhardt, S., Wurst, W. & Ortiz, O. (2015). Development of an intein‐mediated split‐Cas9 system for gene therapy. In Nucleic Acids Research 43 (11), E70.Google Scholar
  22. WADA (2015). Wada‐Verbotsliste. Online‐Quelle: http://www.nada.de/de/medizin/imkrankheitsfall/die‐verbotsliste‐der‐wada (letzter Zugriff: 09.07.2015).Wagner, K. R., Fleckenstein, J. L., Amato, A. A., Barohn, R. J., Bushby, K., Escolar, D. M., Flanigan, K. M., Pestronk, A., Tawil, R., Wolfe, G. I., Eagle, M., Florence, J. M., King, W. M., Pandya, S., Straub, V., Juneau, P., Meyers, K., Csimma,Google Scholar
  23. C., Araujo, T., Allen, R., Parsons, S. A., Wozney, J. M., Lavallie, E. R. & Mendell, J. R. (2008). A phase I/IItrial of MYO‐029 in adult subjects with muscular dystrophy. In Annals of Neurology, 63 (5), S. 561‐571.Google Scholar
  24. Wijshake, T., Baker, D. J. & van de Sluis, B. (2014). Endonucleases: new tools to edit the mouse genome. In Biochimica et Biophysica Acta, 1842 (10), S. 1942‐1950.Google Scholar
  25. Wang, Y. X., Zhang, C. L., Yu, R. T., Cho, H. K., Nelson, M. C., Bayuga‐Ocampo, C. R., Ham, J., Kang, H. & Evans, R. M. (2004). Egulation of muscle fiber type and running endurance by PPARdelta. In PLoS biology, 2 (1), S. 294‐299.Google Scholar
  26. Yesalis, C. (Hrsg.) (2000). Anabolic Steroids in Sport and Exercise. Champaign: Human Kinetics.Google Scholar
  27. Zhang, L. (2011). Exogenous plant MIR168a specifically targets mammalian LDLRAP1: evidence of cross‐kingdom regulation by microRNA. In Cell Research, 22 (1), S. 107‐126.Google Scholar

Copyright information

© Springer Fachmedien Wiesbaden 2016

Authors and Affiliations

  1. 1.Institut für Kreislaufforschung und SportmedizinDeutsche Sporthochschule KölnKölnDeutschland

Personalised recommendations